Sana Biotechnology (NASDAQ:SANA) Stock Price Up 9.8% – Still a Buy?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s share price rose 9.8% during trading on Friday . The stock traded as high as $3.13 and last traded at $3.09. Approximately 918,829 shares traded hands during trading, a decline of 92% from the average daily volume of 11,936,086 shares. The stock had previously closed at $2.81.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SANA. HC Wainwright upped their price target on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Stock Performance

The company’s 50-day moving average price is $2.66 and its two-hundred day moving average price is $3.61.

Insider Activity at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

Several large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Sana Biotechnology by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company’s stock valued at $77,000 after purchasing an additional 4,554 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Sana Biotechnology by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock worth $146,000 after buying an additional 5,338 shares during the period. Teacher Retirement System of Texas lifted its stake in Sana Biotechnology by 20.3% during the fourth quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company’s stock valued at $60,000 after buying an additional 6,209 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Sana Biotechnology by 51.0% in the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company’s stock worth $32,000 after buying an additional 6,694 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Sana Biotechnology by 2.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock worth $1,056,000 after acquiring an additional 6,823 shares in the last quarter. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.